VR Logo

Athenex Inc. (ATNX) download report


Healthcare | Drugs & Pharma

Athenex Inc. (ATNX) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

IPO Date: 14-Jun-2017

Chairman & CEO: Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.

COO & Pres of Athenex Pharmaceutical Division: Mr. Jeffrey M. Yordon

Listing: NASDAQ: ATNX

Country: United States

Headquarters: Buffalo, NY

Website: https://www.athenex.com

Key Facts

Market cap: $48.42 Mln

Revenue (TTM): $108.88 Mln

Earnings (TTM): $-192.14 Mln

Cash: $37.46 Mln

Total Debt: $133.74 Mln

Insider's Holding: 13.19%

Liquidity: Low

52 Week range: $0.41 - 4.53

Shares outstanding: 111,830,000

8 Years Aggregate:

  • CFO: $-655.43 Mln
  • EBITDA: $-813.53 Mln
  • Net Profit: $-876.62 Mln

Stock Performance

Time Period Athenex (ATNX) S&P BSE Healthcare* S&P Small-Cap 600*
YTD-64.19-16.34-18.67
1 month-1.42-0.55-8.32
3 months-46.42-11.78-14.04
1 Year-89.32-15.85-16.76
3 Years-70.4019.906.23
5 Years-50.669.045.72
10 Years--12.199.63
As on 05-Jul-2022 *As on 06-Jul-2022
Year Athenex (ATNX) S&P Small-Cap 600 S&P BSE Healthcare
2021-87.7025.2720.87
2020-27.579.5761.45
201920.3320.86-3.55
2018-20.09-9.70-5.89